A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)
Grant Data
Project Title
A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Wang Julie Kwan Ling
(Co-Investigator)
Dr Lam David Chi Leung
(Co-Investigator)
Dr Wong Matthew King Yan
(Co-Investigator)
Dr Lam Jamie Chung Mei
(Co-Investigator)
Duration
53
Start Date
2009-04-01
Amount
358316
Conference Title
A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)
Presentation Title
Keywords
stage IIIB/V NSCLC
Discipline
Respiration,Cancer
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2008
Status
On-going